NCT04037358View on ClinicalTrials.gov

RAdium-223 and SABR Versus SABR for Oligometastatic Prostate Cancers

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

64

Participants

Timeline

Start Date

August 9, 2019

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2028

Conditions
Prostate Cancer
Interventions
DRUG

Radium-223

Radium-223 plus SABR will be within two weeks.

RADIATION

stereotactic ablative radiotherapy (SABR)

SABR 1-5 fractions

Trial Locations (1)

21287

Johns Hopkins, Baltimore

Sponsors

Collaborators (1)

Bayer
All Listed Sponsors
collaborator

Department of Defense Congressionally Directed Medical Research Program

UNKNOWN

collaborator

Bayer

INDUSTRY

lead

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

OTHER

NCT04037358 - RAdium-223 and SABR Versus SABR for Oligometastatic Prostate Cancers | Biotech Hunter | Biotech Hunter